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Objectives:  Smoking  is  the  major  risk  factor  for lung  and  head  and  neck  cancer.  The purpose  of the  present
study  was  to determine  the  clinical  impact  of  serendipitously  revealed  head  and  neck  ﬁxation  on  PET/CT
in patients  undergoing  investigation  for  lung  cancer.
Material  and methods:  The  reports  from  PET/CT  studies  for  patients  with  lung  cancer  from  September  2005
and April  2012  were  retrospectively  reviewed.  Head  and  neck  incidentaloma  was  interpreted  as  sugges-
tive  of  second  primary  malignancy.  These  incidental  ﬁndings  were  compared  with  the  ﬁnal  diagnosis
obtained  from  clinical  and  histological  investigation.
Results: Five  hundred  and  ninety-two  patients  were  investigated  on PET/CT  for  lung  cancer  in the study
period.  PET/CT-positive  head  and  neck  lesions  suggestive  of  second  primary  malignancy  were  found  in
65 (11%)  patients.  Nasoendoscopy  was  performed  in  23 patients  and  biopsy  in 10. In 4  patients  (17.4%  of
those  explored),  a  second  primary  malignant  lesion  was  proved  on  histology:  2  squamous  cell  carcinomas
(larynx  and  oral  cavity),  1 undifferentiated  carcinoma  (parotid),  and  1 osteosarcoma  (mandible).  At  a
median  13  months’  follow-up,  3  of the 4 patients  with  a second  primary  had  died from  disease-related
causes  and  1 was  free  of  recurrence.  Metastases  from  lung  adenocarcinoma  were  found  in  2 patients
(0.34%).
Conclusions:  PET/CT  detected  incidental  head  and  neck  malignant  tumors  in  at least  0.68%  of lung  cancer
patients,  but  in 6.4%  of  those  with  suspect  head  and  neck  ﬁxation.. Introduction
[18F]FluoroDeoxyGlucose positron emission tomography (18F-
DG) associated to CT (PET/CT) is currently implemented in
ronchopulmonary and head and neck oncology. In the upper
erodigestive tract, malignant lesions exceeding 1 cm and certain
enign lesions ﬁx under PET/CT. Lung and head and neck cancers
ave the same principal risk factor: smoking. The upper aerodiges-
ive tract often shows physiological ﬁxation on PET/CT.
Between September 2005 and April 2012, 592 lung-cancer
atients had at least one PET/CT examination. The present study
nalyzed incidental ENT ﬁxations, how many of them led to
omplementary examination and what was the diagnosis of patho-
ogical lesions.
∗ Corresponding author. Tel.: +33 02 98 22 33 78.
E-mail addresses: remi.marianowski@chu-brest.fr, r.marianowski@free.fr
R. Marianowski).
879-7296/$ – see front matter © 2014 Published by Elsevier Masson SAS.
ttp://dx.doi.org/10.1016/j.anorl.2013.06.004©  2014  Published  by Elsevier  Masson  SAS.
The meaning of such incidentally discovered ﬁxation and the
procedure to be adopted in consequence are discussed.
2. Material and methods
All patients with lung cancer of primary aspect undergoing at
least one 18F-FDG PET/CT examination for diagnosis, assessment or
follow-up in the Nuclear Medicine Department of our University
Hospital between September 2005 and April 2012 were included.
Patients with history of ENT neoplasia were excluded.
Examination was on a hybrid Gemini GXLi PET/CT machine
(Philips®), associating a 6-slice Brilliance CT scanner and GSO-Zr
crystal PET, each measuring 4 × 6 × 30 mm.
Acquisitions were taken 60 minutes after injection of approx-
imately 370 MBq  (5–6 MBq/kg) 18F-FDG. All patients fasted for at
least 6 hours before examination. After injection, a calm rest period
was imposed, with no speaking or reading, so as to minimize phys-
iological muscle ﬁxation. Images were interpreted, visually and
quantitatively by standardized uptake value (SUV), by a senior
member of the nuclear medicine department.
2 ngology, Head and Neck diseases 131 (2014) 217–221
w
“
c
U
“
c
a
w
l
w
t
3
a
n
w
(
n
u
a
T
g
f
4
t
m
d
a
e
h
E
f
c
p
b
t
a
s
D
n
g
Table 1
Distribution of number of PET/CTs per patient and number of ENT ﬁxations.
Number of PET/CTs Number of patients Number of patients
with ENT ﬁxation
1 406 (68.6%) 37 (9.1%)
2 125 (21.1%) 13 (10.4%)
3 36 (6.1%) 9 (25%)
T
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Upper aerodigestive tract ﬁxation was considered signiﬁcant
hen the nuclear medicine specialist assessed it as “suspect”,
requiring complementary exploration” or “to be compared with
linical ﬁndings”; otherwise, it was simply mentioned in the report.
pper aerodigestive tract ﬁxations considered “physiological” or
non-pathological” were not taken into account.
The locations studied were the facial sinuses, rhinopharynx, oral
avity, salivary glands, oropharynx, hypopharynx, larynx, thyroid
nd cervical lymph nodes, excluding the supraclavicular region
hich is the usual location for regional lymph node metastasis from
ung cancers.
Patients with several PET/CT examinations were counted if there
as at least one incidental ﬁxation in the upper aerodigestive
ract.
. Results
In all, 592 patients were included: 447 male, 145 female; mean
ge, 62 years (range, 22–85 years; median, 62 years).
Three hundred and forty-eight patients (58.8%) showed lymph-
ode extension and 114 (19.2%) remote extension. Histological type
as known in 193 patients at initial PET/CT: 84 adenocarcinomas
43.5%), 80 squamous cell carcinomas (41.5%), 20 small-cell carci-
omas (10.2%), 3 carcinoid tumors (1.5%), 3 lymphomas (1.5%), 2
ndifferentiated carcinomas (1%) and 1 ﬁbrosarcoma (0.5%).
Eight hundred eighty-six PET/CT reports for 592 patients were
nalyzed. There were a mean 1.5 PET/CTs per patient (range, 1–6:
able 1). Sixty-ﬁve patients (11%) showed signiﬁcant upper aerodi-
estive tract ﬁxation on at least one examination: 47 male, 18
emale; mean age, 60 years 9 months (median, 60 years; range,
2–84 years). On the ﬁrst examination showing a suspect lesion,
he SUVmax value was recorded in the report in 56 cases (86.2%):
ean SUVmax, 4.5 ± 3.3; median, 3.5; range, 1.5–23.3.
Only 45 of the 65 patients (69.2%) were being followed in the
epartment. The other 20 came speciﬁcally for PET/CT, little avail-
ble outside university hospitals, and were followed up clinically
lsewhere; research was undertaken to ﬁnd out whether they had
ad an ENT consultation by telephoning regional hospitals with
NT departments, or patients’ family physicians.
The following problems were encountered: patient death too
ar in the past; physician retired or deceased; no apparent ENT
onsultation; no medical records; no personal physician.
It was therefore decided to make inquiries in the regional
athology departments and ofﬁces, not about ENT consultations
ut about any ENT malignancy. None could be demonstrated in
hese 20 patients.
Only 23 of the 45 patients managed at the university hospital
nd presenting suspect upper aerodigestive tract ﬁxation had a con-
ultation for this indication in the ENT and Head and Neck Surgery
epartment. The other 22 had no specialist consultation, as it did
ot seem justiﬁable to the physicians managing their lung cancer,
iven their general health status or prognosis.
able 2
umber of ENT ﬁxations discovered on PET/CT, of malignancies and of histologic type pe
Signiﬁcant ENT ﬁxation location Number of patients 
Larynx 18 (27.7%) 
Jugulocarotid lymph-node areas 17 (26.2%) 
Oropharynx 10 (15.3%) 
Oral  cavity 9 (13.8%) 
Parotid  6 (9.2%) 
Thyroid 6 (9.2) 
Rhinopharynx 4 (6.2%) 
Hypopharynx 3 (4.6%) 
Submaxillary gland 1 (1.5%) 4 17 (2.9%) 4 (23.5%)
5 6 (1%) 0 (0%)
6 2 (0.3%) 2 (100%)
For each of the 23 patients, ENT examination comprised clinical
and ﬁberoptic endoscopic examination. Ten also underwent upper
gastrointestinal endoscopy under general anesthesia with biopsy.
Eighteen of the 23 patients had PET/CT reports that included
SUVmax. Mean SUVmax was 4.7. Histology found 6 malignant
lesions: 2 squamous cell carcinomas, 2 adenocarcinomas of pul-
monary origin, 1 undifferentiated carcinoma and 1 osteosarcoma
(Table 2); there were also 2 benign lesions: 1 malpighian papilloma
and 1 epidermoid cyst.
Thus, 6 malignancies were detected in the 45 university hospital
patients showing upper aerodigestive tract ﬁxation (13.3%). When
an ENT consultation took place, malignancy was diagnosed in 26%
of cases. SUVmax was noted in 5 of the 6 PET/CT reports of ENT
ﬁxation. Mean SUVmax was 4.16 ± 1.3.
A malignant lesion of the upper aerodigestive tract unrelated to
the lungs was found in 4 of the 45 patients (8.9%) (Table 3).
The ﬁrst was a 68-year-old woman, presenting with left supe-
rior lobe T2N0M0 squamous cell carcinoma, managed surgically.
PET/CT found ﬁxation in the oropharynx and left ascending branch
of the mandible (SUVmax, 5.1). The patient reported mandibu-
lar and oropharyngeal pain. High-malignancy T3N1M0 left
mandibular osteosarcoma was diagnosed. Treatment comprised
transmandibular oropharyngectomy associated to cervical lymph
node resection and complementary radiation and chemotherapy.
Survival was 11 months. The cause of death was evolution of
mandibular osteosarcoma.
The second patient was  a 73-year-old man, presenting with right
superior lobe T1N1M0 squamous cell carcinoma, managed surgi-
cally. PET/CT found ﬁxation in the right superior and medial thyroid
cartilage (SUVmax, 3.6) and right vocal fold (SUVmax, 2.6). The
patient was dysphonic on ENT consultation. Subglottic T4aN2bM0
squamous cell carcinoma of the laryngeal side of the epiglottis was
diagnosed. Treatment comprised total laryngectomy associated to
bilateral cervical lymph node resection and complementary radia-
tion and chemotherapy. Survival was  31 months. The cause of death
was local recurrence of the laryngeal lesion.
The third patient was  a man  of 55 years at diagnosis, presenting
with right superior lobe T1aN0M0 squamous cell carcinoma, man-
aged by radiation and chemotherapy. PET/CT (Fig. 1) found right
oral cavity ﬁxation (SUVmax, 2.8) and right sector IIa cervi-
cal ﬁxation (SUVmax, 2.3). There was no ENT symptomatology.
T2N1M0 squamous cell carcinoma of the right retromolar region
was diagnosed. Treatment was  exclusively radiation therapy. At
r ENT location.
Number of malignancies Histologic type
1 Squamous cell carcinoma
2 Adenocarcinoma
1 Osteosarcoma
1 Squamous cell carcinoma
1 Undifferentiated carcinoma
0
0
0
0
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Table  3
Characteristics of patients with malignancy unrelated to the lungs.
Patient Gender Age (years) Fixation Histology and TNM SUVmax Treatment Survival
Patient 1 Female 68 Oropharynx and
ascending mandibular
branch
Osteosarcoma T3N1M0 5.1 Surgery,
radiotherapy and
chemotherapy
Death at
11 months’ FU
Patient 2 Male 73 Thyroid cartilage Squamous cell
carcinoma T4N2bM0
3.6 Surgery,
radiotherapy and
chemotherapy
Death at
31 months’ FU
Patient 3 Male 55 Oral cavity Squamous cell
carcinoma T2N1M0
2.8 Radiotherapy Recurrence-free
survival at
ndiff
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tPatient 4 Female 52 Parotid U
c
he time of writing, the patient was in good health at 13 months’
ollow-up.
The fourth patient was a 52-year-old woman  presenting
ith left inferior lobe T2N2M1 adenocarcinoma, managed by
hemotherapy. PET/CT found right intraparotid ﬁxation (SUV not
peciﬁed). There was no ENT symptomatology. T1N1M0 undiffer-
ntiated parotid carcinoma was diagnosed. Treatment comprised
otal right parotidectomy associated to right cervical lymph node
esection of sectors IIa and IIb with complementary radiation ther-
py. Survival was 13 months. The cause of death was metastasis of
he pulmonary lesion.
In these 4 patients, mean SUVmax was 3.8. Three died, with a
ean 18.3 ± 11 and median 13 months’ survival.
PET/CT in a context of lung cancer led to diagnosis of a head and
eck malignancy in 0.68% of cases and of primary cancer in 0.34%
Fig. 2).
ig. 1. PET, CT and combined PET/CT enabling visualization of an oral cavity lesion (classiﬁ
his  anterior ﬁxation in patient 3.13 months’ FU
erentiated
oma T1N1M0
NC Surgery and
radiotherapy
Death at
13 months’ FU
4. Discussion
The upper aerodigestive tract typically shows physiological ﬁx-
ation. Asymmetric ﬁxation, elevated SUV or an unusual location,
however, will be noted in the nuclear medicine report. The clinician
who ordered the examination then decided whether to undertake
further exploration. In the present study, head and neck malignancy
was diagnosed in more than a quarter of the patients who had ENT
consultation after incidental discovery of abnormalities on PET/CT.
ENT consultation, on the other hand, concerned only 23 of the
45 patients (51.5%) with ENT ﬁxation discovered on PET/CT who
were managed in the center (51.5%). This seems a low rate, given
that PET/CT detects ENT malignancy with high sensitivity and speci-
ﬁcity [1,2] and that these patients had risk factors for such tumors.
In the present series, however, patients had lung cancer, with its
poor prognosis [3]. For example, at least 2 of the 45 had less than
ed T2) originating in the retromolar trigone and extending to the oral ﬂoor–whence
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fFig. 2. Flowchart of the principal study results.
 month’s survival. It is therefore understandable that complemen-
ary examination may  not have seemed justiﬁable to the clinicians
anaging these patients, especially when asymptomatic.
Most PET/CT examinations were carried out to assess tumoral
xtension as part of pre-treatment operability assessment. Thus
atients already known to have metastasis or in whom surgical
esection is impossible will not undergo PET/CT in this indication.
urgical resection is impossible in 80% of lung cancers at diagno-
is [4]. The present study population of 592 patients was thus not
epresentative of lung cancer patients in general, but contained a
election bias in favor of good prognosis.
SUV is used to assess the risk that PET/CT ﬁxation reveals
 malignant lesion. It is not, however, totally reliable. PET is a
etabolic-based imaging technique, and SUV does not show good
ntersubject reproducibility; even in a given individual, variations
n glycemia may  affect SUV [5]. It may  also vary during updating
f calibration software or equipment repair [6]. It frequently varies
y more than 10% for a given examination performed on different
achines under identical conditions [7]. Moreover, SUV is not sys-
ematically noted in all PET/CT reports. In the present study, the
ean SUVmax for suspect ENT lesions was 4.5, and 4.16 in proven
alignancy. According to the literature, malignancy should be sus-
ected when SUV exceeds 2.5 to 3.8 [5]. Nghi C. Nguyen et al. [8]
eported a SUVmax threshold of 2.2 in the cervical lymph-node
reas, with 98% sensitivity and 83% speciﬁcity.
Suspect ﬁxation mainly concerned 2 locations, the larynx and
he jugulocarotid areas, which accounted for about half of all ﬁx-
tions found. Oral cavity and oropharyngeal ﬁxations were not
nusual. Other locations were rarer. Notably, the parotid, despite
howing physiological ﬁxation on PET/CT, like the tonsils, vocal
olds and tongue [9,10], represented only 9.2% of suspect ﬁxations.y, Head and Neck diseases 131 (2014) 217–221
This is why  analysis was based not on absolute SUV but on abnormal
ﬁxation: asymmetry or unusual location.
Repeating PET/CT in each patient seemed to increase the proba-
bility of discovering upper aerodigestive tract hyperﬁxation: while
the mean rate was 11.7%, it was only 9.1% in patients undergoing a
single PET/CT examination, and rose to 25% in those who  had 3.
For the PET/CTs analyzed, initial assessments and lung-cancer
surveillance reports were included without distinction, as the study
did not focus on synchronicity versus metachronicity but purely on
malignancy and incidental ﬁxation.
Two of the 6 upper aerodigestive tract malignancies discovered
on PET/CT were metastases of lung cancer. Only 2 of the 4 primary
lesions discovered were squamous cell carcinomas of the upper
aerodigestive tract. The mandibular osteosarcoma and the undif-
ferentiated parotid carcinoma had no proven relationship with
smoking, the principal risk factor for ENT and lung cancer, and the
starting point of the present study [3].
All the patients in whom ENT cancer was discovered received
treatment, which was  surgical in 75% of cases. Survival was  never-
theless less than 2 years. The study design shed no light on whether
diagnosis improved survival or quality of life.
The primary malignant upper aerodigestive tract lesions discov-
ered were large (T3 or T4) in half the cases. It is remarkable that, in
patients regularly followed up for their lung pathology, such ENT
lesions should have gone undetected on clinical signs, especially as
the patients reported functional signs during ENT consultation.
Few studies have focused on incidental discovery of upper
aerodigestive tract lesions on PET/CT [11]. In a retrospective study
of 812 patients undergoing PET/CT for lung cancer, Chopra et al. [11]
found unexpected suspect extrathoracic ﬁxation in 22% of cases
and in the upper aerodigestive tract in 8.8%. In the present series,
the rate was higher: 11%. However, Chopra et al. analyzed only the
ﬁrst PET/CT in each patient. Patients with only one PET/CT in the
present series showed a 9.1% rate of suspect upper aerodigestive
tract ﬁxation, close to Chopra et al.’s ﬁnding. They explored 55%
of suspect upper aerodigestive tract ﬁxation, compared to 51.1% in
the present study. Advanced pulmonary pathology was  the main
reason given for failure to explore certain patients. A single pri-
mary upper aerodigestive tract cancer was ﬁnally diagnosed in their
series: i.e., only 1.4% of suspect ﬁxations and 0.12% of included
patients, compared to respectively 8.9% and 0.68% in the present
study. The low number of cancers ﬁnally diagnosed in both studies
can account for this difference.
In a retrospective study of 1912 patients undergoing PET for
proven or suspected malignancy at whatever location, Ishimori
et al. [12] found suspect ENT ﬁxation in 2% of cases. Upper aerodi-
gestive tract malignancy was proved in only 0.37% of cases. Only the
ﬁrst PET was  analyzed. These rates are lower than in the present
study. Thus, a second primary of the head and neck may  be more
frequently discovered on PET/CT when performed in the context
of lung cancer. In Ishimori et al.’s study, however, when suspect
ENT ﬁxation was  explored malignancy was discovered in 41% of
cases, compared to only 23% in the present study. Thus, their study
involved fewer false positives, although based on PET examination
without CT.
Beatty et al. [2] studied all the PET/CTs of 2219 patients, and
found suspect ENT ﬁxation or a second primary in only 3.3% of
cases, regardless of the location of the tumor for which PET/CT was
performed. In 20% of cases, however, PET/CT was performed in a
context of upper aerodigestive tract cancer, so that discovery of a
new ENT ﬁxation cannot be counted as raising suspicion of a second
primary location.The thyroid is a common location for suspect ﬁxation on PET/CT.
It may  show hyperﬁxation under various pathological conditions,
including cancer [9,13–16]. It is the location of suspect unex-
pected ﬁxation on PET/CT in 1.1% to 8.4% of cases, revealing thyroid
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alignancy in 14% to 66% of cases [13–16]. In the present study,
uspect thyroid ﬁxation was found in only 1% of patients, and no
hyroid cancers were diagnosed.
In the above retrospective studies, false negatives cannot be
ssessed, as patients without suspect head and neck ﬁxation did not
ave complementary upper aerodigestive tract exploration. Jeong
on Lee et al. [17] performed PET/CT in 1587 volunteer patients
ith no history of malignancy, as part of a prospective cancer
creening study. Other kinds of imaging, various endoscopies and
umor marker assays were performed, with at least 1 year’s clini-
al follow-up. There was only one false negative in the head and
eck region: a papillary thyroid cancer, revealed by cervical ultra-
ound. This conﬁrms the excellent sensitivity of PET/CT in detecting
alignant tumors of the head and neck.
In all of these studies, despite large sample sizes, the numbers
f malignancies discovered were low. It is up to the clinician to
ecide whether it is worthwhile performing complementary exam-
nations on discovery of a suspect ﬁxation. PET/CT is highly sensitive
n detecting upper aerodigestive tract cancer and the population
f lung cancer patients is especially exposed to the risk of upper
erodigestive tract cancer. At the same time, these patients tend to
ave poor general health status, so that exploring ﬁxations may  not
e justiﬁable.
PET/CT is costly; the present study examined upper aerodiges-
ive tract ﬁxations on acquisitions obtained for another indication,
o that no extra cost was incurred.
The present study also raises the issue of double ENT and
ronchopulmonary tumor locations, with their adverse impact
n prognosis [18,19]. Discovery of a double location should not,
owever, be taken as contraindicating the surgical treatment that
ould have been performed for a single location [18,19]. Treatment
ptions in these synchronous or metachronous tumors should be
iscussed on a case-by-case basis, according to general health sta-
us and comorbidity. Synchronous tumors have poorer prognosis
han metachronous tumors and also raise the problem of order
f treatment [19,20]. When surgery is decided on, the pulmonary
esion is generally operated on ﬁrst, enabling histologic diagnosis
o rule out metastasis of the upper aerodigestive tract cancer and a
onsequently more adverse prognosis.
. Conclusion
PET/CT in a context of lung cancer diagnosed a malignant lesion
f the head and neck in 0.68% of cases and a primary cancer in
.34%. Suspect head and neck ﬁxations on PET/CT are frequent,
nd often raise the problem for the physician of how to manage
hem. In 23 patients who had ENT consultation, there was  a 26%
ate of diagnosis of malignant tumor, modifying the initial treat-
ent attitude, with speciﬁc treatment in 4 cases (17% of patients
xplored), which is by no means negligible. It can therefore be
fﬁrmed that, in case of pathologic ENT ﬁxation, ENT examination
hould imperatively be undertaken if the patient’s general health
tatus and pulmonary carcinoma prognosis permits. In the present
tudy, malignant lesions of the head and neck were diagnosed in
[y, Head and Neck diseases 131 (2014) 217–221 221
more than a quarter of the patients who had ENT consultation after
incidental discovery of abnormality on PET/CT.
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